Cavu Management, LP's Form 4 filing
Lantern Pharma Inc. (LTRN) · filed May 29, 2025
- Accession no.
- 0001104659-25-054421
- Filed
- May 29, 2025, 9:53 PM ET
- Trade date
- May 27-29, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 15 non-derivative transactions. Open-market sales total $168.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cavu Management, LPCIK 0001813270 | 10% Owner |
| Cavu Advisors, LLCCIK 0001813310 | 10% Owner |
| BP Directors, LPCIK 0001813311 | 10% Owner |
| Kreis Leslie W.CIK 0001813316 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 27, 2025 | Common Stock | SSaleDisposed | −3,790 | $3.05F1 | −$11,559.5 | 213,763 | Indirect | |
| May 28, 2025 | Common Stock | SSaleDisposed | −2,702 | $2.87F2 | −$7,754.74 | 211,061 | Indirect | |
| May 29, 2025 | Common Stock | SSaleDisposed | −3,639 | $3.03F3 | −$11,026.17 | 207,422 | Indirect | |
| May 27, 2025 | Common Stock | SSaleDisposed | −6,479 | $3.05F1 | −$19,760.95 | 365,471 | Indirect | |
| May 28, 2025 | Common Stock | SSaleDisposed | −4,620 | $2.87F2 | −$13,259.4 | 360,851 | Indirect | |
| May 29, 2025 | Common Stock | SSaleDisposed | −6,221 | $3.03F3 | −$18,849.63 | 354,630 | Indirect | |
| May 27, 2025 | Common Stock | SSaleDisposed | −1,000 | $3.05F1 | −$3,050 | 56,467 | Indirect | |
| May 28, 2025 | Common Stock | SSaleDisposed | −714 | $2.87F2 | −$2,049.18 | 55,753 | Indirect | |
| May 29, 2025 | Common Stock | SSaleDisposed | −961 | $3.03F3 | −$2,911.83 | 54,792 | Indirect | |
| May 27, 2025 | Common Stock | SSaleDisposed | −7,478 | $3.05F1 | −$22,807.9 | 421,808 | Indirect | |
| May 28, 2025 | Common Stock | SSaleDisposed | −5,332 | $2.87F2 | −$15,302.84 | 416,476 | Indirect | |
| May 29, 2025 | Common Stock | SSaleDisposed | −7,180 | $3.03F3 | −$21,755.4 | 409,296 | Indirect | |
| May 27, 2025 | Common Stock | SSaleDisposed | −2,290 | $3.05F1 | −$6,984.5 | 129,163 | Indirect | |
| May 28, 2025 | Common Stock | SSaleDisposed | −1,632 | $2.87F2 | −$4,683.84 | 127,531 | Indirect | |
| May 29, 2025 | Common Stock | SSaleDisposed | −2,199 | $3.03F3 | −$6,662.97 | 125,332 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. On May 27, 2025 each of Bios Fund I QP, LP ("Bios Fund I QP"), Bios Fund I, LP ("Bios Fund I"), Bios Fund II NT, LP ("Bios Fund II NT"), Bios Fund II QP, LP ("Bios Fund II QP") and Bios Fund II, LP ("Bios Fund II") sold shares in multiple transactions at prices ranging from $2.87 to $3.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
Referenced by the price of 5 transactions in Table I.
- F2
The price reported in Column 4 is a weighted average price. On May 28, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $2.85 to $2.94 inclusive.
Referenced by the price of 5 transactions in Table I.
- F3
The price reported in Column 4 is a weighted average price. On May 29, 2025, each of Bios Fund I QP, Bios Fund I, Bios Fund II NT, Bios Fund II QP and Bios Fund II sold shares in multiple transactions at prices ranging from $3.00 to $3.13 inclusive.
Referenced by the price of 5 transactions in Table I.
Remarks
Exhibit 24 - Power of Attorney. This Form 4 is the second of two Forms 4 filed relating to the same event. The Form 4 has been split into two filings because there are more than 10 reporting persons in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 reporting person. The first Form 4 was filed by Aaron Glenn Louis Fletcher as the designated filer.